SULT2B1: a novel therapeutic target in colorectal cancer via modulation of AKT/PKM2-mediated glycolysis and proliferation
Journal of Translational Medicine · 2024
DOI: 10.1186/s12967-024-05910-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Translational Medicine, 2024. Verfasst von Jianxing Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins c-akt, Cell Proliferation, Glycolysis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Project of Shandong Province Higher Educational Science and Technology Program.
Abstract (Originalsprache)
BACKGROUND: Sulfotransferase family 2B member 1 (SULT2B1) is involved in regulating cell proliferation, migration and metabolism. However, there is still dispute regarding whether SULT2B1 acts as an oncogene or a suppressor, and the intrinsic mechanisms in modulating tumor progression need to be further elucidated. METHODS: This work aims to reveal the relationship among SULT2B1, AKT, PKM2 signaling and glycolytic pathways, and provided a theoretical basis for SULT2B1 as a potential therapeutic target for CRC.Bioinformatics methods, immunohistochemistry (IHC) and immunoblotting assays were performed to analyze the correlation between SULT2B1 and colorectal cancer (CRC). The effect of SULT2B1 on cell proliferation and migration were investigated by several phenotypic experiments in vitro and animal studies. The SULT2B1 interacting proteins were determined by immunofluorescence, immunoprecipitation and GST-pull down assays. Immunoblotting and mCherry-GFP-LC3 assays were performed to analysis autophagy. Chromatin immunoprecipitation (CHIP) assay was utilized to detect the effect of SULT2B1 in regulating transcription. Small molecule agonist/antagonist was used to modify protein activity and therefore analyze the mutual relationships. RESULTS: SULT2B1 is a predictive biomarker that is abnormally overexpressed in CRC tissues. Overexpression of SULT2B1 promoted cell proliferation and migration, while its knockout suppressed these processes. Furthermore, SULT2B1 could directly interact with the oncogene AKT and thereby enhance the activity of AKT-mTORC1 signaling. Furthermore, PKM2 was found to bind with SULT2B1, and regulated by SULT2B1 at both transcription and degradation levels. Moreover, blocking glycolysis attenuated the promoting effect of OE-SULT2B1. CONCLUSION: SULT2B1 acts as an oncogene in CRC via modulating the AKT/PKM2 axis, therefore making it a promising diagnostic and therapeutic target for CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, China.
- Precision Medicine Laboratory for Chronic Non-Communicable Diseases of Shandong Province, Institute of Precision Medicine, Jining Medical University, Jining, 272067, China.
- Precision Medicine Laboratory for Chronic Non-Communicable Diseases of Shandong Province, Institute of Precision Medicine, Jining Medical University, Jining, 272067, China. yansy@mail.jnmc.edu.cn.
- Department of General Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, China. chenwang@lzu.edn.cn.
ORCID-Profile: Siyuan Yan
Förderung
- the National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Project of Shandong Province Higher Educational Science and Technology Program
- Science and Technology Program of Gansu Province
Zitieren
APA
Ma, J., Sun, F., Li, W., Du, R., Liu, M., Wei, Q., Kang, B., Yan, S., & Wang, C. (2024). SULT2B1: a novel therapeutic target in colorectal cancer via modulation of AKT/PKM2-mediated glycolysis and proliferation. Journal of Translational Medicine. https://doi.org/10.1186/s12967-024-05910-4
Vancouver
Ma J, Sun F, Li W, Du R, Liu M, Wei Q, et al. SULT2B1: a novel therapeutic target in colorectal cancer via modulation of AKT/PKM2-mediated glycolysis and proliferation. Journal of Translational Medicine. 2024. doi:10.1186/s12967-024-05910-4
BibTeX
@article{Ma2024,
author = {Ma, Jianxing and Sun, Fengyao and Li, Wen and Du, Ruihang and Liu, Mingchan and Wei, Qiuya and Kang, Boxiong and Yan, Siyuan and Wang, Chen},
title = {SULT2B1: a novel therapeutic target in colorectal cancer via modulation of AKT/PKM2-mediated glycolysis and proliferation},
journal = {Journal of Translational Medicine},
year = {2024},
doi = {10.1186/s12967-024-05910-4}
}
EUVIMED